Table 2.
T cell data
| Parameter | Values for indicated group [median (IQR)] or individual values | ||||||
|---|---|---|---|---|---|---|---|
| Control | Asymptomatic | Acute uncomplicated | |||||
| Sub-microscopic | Sub-microscopic | Patent | Patent | Malaria | Malaria | ||
| P. falciparum | P. vivax | P. falciparum | P. vivax | P. falciparum | P. vivax | ||
| No. of subjects | 70 | 17 | 12 | 12 | 18 | 6 | 8 |
| CD4 T cells/µl blood | 752 (611–914) | 570 (478–699)a | 733 (634–1165) | 836 (539–1041) | 773 (588–941) | 201 (117–351)** | 243 (170–321)*** |
| CD25+ CD127low CD4+ Treg cells/µl blood | 42 (33–53) | 36 (28–46) | 44 (40–59) | 41 (33–66) | 41 (30–54) | 14 (11–23)** | 16 (11–21)*** |
| % of Treg cells in CD4 T cells | 5.4 (4.6–6.2) | 6.1 (5.2–7.2) | 6.0 (4.1–6.9) | 6.3 (5.4–7.1) | 5.3 (4.4–6.5) | 6.9 (5.7–9.7) | 6.3 (5.6–7.4) |
| CD45RA− CD25high aTreg/µl blood | 8.0 (6.1–11.2) | 7.7 (5.9–10.2) | 8.2 (6.6–12.9) | 7.1 (2.8–9.9) | 6.0 (5.3–7.3)a | 3.9 (2.6–5.0)* | 4.3 (3.3–7.4)a |
| % of aTreg in total Treg cells | 20.7 (16.2–25.8) | 23.5 (17.9–28.0) | 19.8 (15.3–22.9) | 11.9 (8.6–16.4)** | 14.8 (13.0–18.1)a | 25.2 (20.1–33.8) | 29.2 (26.3–44.4)* |
| CD45RA+ CD25+ rTreg/µl blood | 12.3 (6.6–19.3) | 8.9 (6.8–13.9) | 14.0 (7.6–20.0) | 11.7 (9.3–19.3) | 10.0 (7.2–17.8) | 4.4 (3.1–6.0)* | 2.9 (1.7–4.1)*** |
| % of rTreg in total Treg cells | 31.7 (20.5–36.9) | 29.3 (21.1–35.2) | 27.7 (21.1–35.5) | 30.8 (22.3–36.2) | 28.6 (23.4–38.4) | 30.2 (19.1–33.4) | 19.4 (14.2–20.5)* |
| rTreg/aTreg ratio | 1.3 (0.9–1.9) | 1.0 (0.8–2.0) | 1.2 (0.9–2.5) | 2.3 (1.4–3.7)* | 1.8 (1.3–2.7)a | 1.1 (0.8–1.5) | 0.7 (0.4–0.9)** |
IQR interquartile range
Significantly different to control, Kruskal–Wallis test with Dunn’s multiple comparisons
* P < 0.05
** P < 0.005
*** P < 0.0005
aSignificantly different to control, Mann–Whitney U test (P < 0.05)